Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.

Mochizuki S, Nishimura N, Inoue A, Murakami K, Nukiwa T, Chohnabayashi N.

Respir Investig. 2012 Sep;50(3):117-21. doi: 10.1016/j.resinv.2012.06.002. Epub 2012 Jul 15.

PMID:
23021771
2.

EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.

Shimato S, Mitsudomi T, Kosaka T, Yatabe Y, Wakabayashi T, Mizuno M, Nakahara N, Hatano H, Natsume A, Ishii D, Yoshida J.

Neuro Oncol. 2006 Apr;8(2):137-44. Epub 2006 Jan 20.

3.

Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.

Lin CH, Hsu KH, Chang SN, Tsou HK, Sheehan J, Sheu ML, Pan HC.

Radiat Oncol. 2015 Jun 6;10:127. doi: 10.1186/s13014-015-0431-7.

4.

[Antitumor effects of gefitinib for metastatic brain tumors from lung carcinomas with EGFR mutation].

Ono Y, Toyota Y, Toyoshima A, Kuramoto S, Katzumata A, Kawauchi M, Matsumoto Y.

No Shinkei Geka. 2011 Jun;39(6):569-74. Japanese.

PMID:
21628735
5.

Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations.

Wu JY, Shih JY, Chen KY, Yang CH, Yu CJ, Yang PC.

Medicine (Baltimore). 2011 May;90(3):159-67. doi: 10.1097/MD.0b013e31821a16f4.

6.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group.

N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.

7.

Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.

Yan DF, Yan SX, Yang JS, Wang YX, Sun XL, Liao XB, Liu JQ.

BMC Cancer. 2010 Feb 21;10:49. doi: 10.1186/1471-2407-10-49. Review.

8.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.

10.

Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study.

Tateishi K, Ichiyama T, Hirai K, Agatsuma T, Koyama S, Hachiya T, Morozumi N, Shiina T, Koizumi T.

Med Oncol. 2013 Mar;30(1):450. doi: 10.1007/s12032-012-0450-2. Epub 2013 Jan 13.

PMID:
23315220
11.

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.

Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Takahashi K, Yamamoto N.

Cancer Sci. 2011 May;102(5):1032-7. doi: 10.1111/j.1349-7006.2011.01887.x. Epub 2011 Feb 28.

12.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
14.

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T.

Clin Cancer Res. 2009 Jul 1;15(13):4493-8. doi: 10.1158/1078-0432.CCR-09-0391. Epub 2009 Jun 16.

15.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS.

Lung Cancer. 2012 Sep;77(3):556-60. doi: 10.1016/j.lungcan.2012.05.092. Epub 2012 Jun 5.

PMID:
22677429
16.

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC.

J Clin Oncol. 2008 Jun 1;26(16):2745-53. doi: 10.1200/JCO.2007.15.6695.

PMID:
18509184
17.

Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.

Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, Matsumura A, Iuchi K, Takada M, Kawahara M, Kawaguchi T, Yukiue H, Yokoyama T, Yano M, Fujii Y.

J Cancer Res Clin Oncol. 2008 May;134(5):569-77. Epub 2007 Oct 12.

PMID:
17932690
18.

Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.

Chen X, Li W, Hu X, Geng Y, Wang R, Yin Y, Shu Y.

Biomed Pharmacother. 2011 Dec;65(8):542-6. doi: 10.1016/j.biopha.2011.04.017. Epub 2011 Jun 12.

PMID:
21840160
19.

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.

Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T.

Lung Cancer. 2011 Mar;71(3):249-57. doi: 10.1016/j.lungcan.2010.12.008. Epub 2011 Jan 8. Review.

PMID:
21216486
20.

Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.

Okamoto I, Takahashi T, Okamoto H, Nakagawa K, Watanabe K, Nakamatsu K, Nishimura Y, Fukuoka M, Yamamoto N.

Lung Cancer. 2011 May;72(2):199-204. doi: 10.1016/j.lungcan.2010.08.016. Epub 2010 Sep 9.

PMID:
20828860

Supplemental Content

Support Center